차바이오텍, 매수조합에 600억 재베팅…차헬스케어 부담 줄인다

CHA Biotech is distributing CHA Healthcare's investor redemption obligations through a private equity syndicate partnership while maintaining operational control, extending the exit timeline to 2028-2029. This restructuring preserves the company's exposure to its global hospital network—representing 59% of consolidated revenue—while addressing near-term funding pressures. The move reflects a strategic choice to retain growth optionality in overseas medical services and regenerative medicine markets rather than pursue a full exit.